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Stimulation of rabbit platelets with U46619 induced platelet shape change, aggregation and secretion of ATP. However, 
S-145, which specifically binds to the thromboxane A,/prostaglandin H, receptor like U46619, induced only shape 
change. Both compounds rapidly elevated cytoplasmic Ca*+ concentration although only U46619 evoked the formation 
of inositol phosphates. Chelating external Caz+ with EGTA did not affect the S-145-induced platelet shape change while 
intracellular Caz+ movement was severely reduced. These results suggest an essential role of phospholipase C in the induc- 
tion of platelet aggregation and secretion and that some factor other than Caz+ and phospholipase C participates in plate- 
let shape change. 
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1. INTRODUCTION 
Platelets are activated by stimulation with many 
physiological agonists [ 11. Platelet activation is 
thought to be promoted by the synergistic action of 
Ca2+ and protein kinase C [2-41. A rise in 
cytosolic Ca2+ concentration is induced by inositol 
1,4,5trisphosphate (IP3), a product of the 
breakdown of phosphatidylinositol 4,5bisphos- 
phate by phospholipase C. Diacylglycerol, another 
product of phospholipase C action, activates pro- 
tein kinase C. 
Three separate physiological responses, shape 
change, aggregation, and secretion, are induced as 
a result of platelet activation. However, the 
biochemical reaction essential to each physiolog- 
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ical response has not been precisely investigated, 
since it is difficult to clearly separate the physiolog- 
ical responses, and the biological responses as well. 
Many agonists usually induce all the responses 
almost simultaneously. 
U46619, an agonist of the thromboxane AZ 
(TXAz)/prostaglandin H2 (PGH2) receptor [5], 
also induces the three physiological responses. 
However, S-145 (( k)-5(Z)-7-(3-endo-phenylsulfo- 
nylamino[2.2.1]bicyclohept-2-exe-yl)heptenoic ac- 
id), a newly synthesized TXA2/PGH2 receptor 
antagonist with an affinity higher than U46619, 
which antagonizes the action of U46619 on 
vascular smooth muscle and platelets [6,7], induces 
only platelet shape change. Therefore, we thought 
that S-145 would be an ideal tool to use in studying 
the signal transduction of platelet shape change. In 
this study we investigated the responses of rabbit 
platelets stimulated with U46619 or S-145 and 
found that activation of phospholipase C was ac- 
companied by induction of aggregation and secre- 
tion, but not by platelet shape change, which was 
induced without a significant increase of cytosolic 
Ca2+. 
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2. MATERIALS AND METHODS 
U46619 was purchased from Upjohn Co., Kalamazoo. S-145 
was synthesized at Shionogi Research Laboratories, Co., Ltd. 
myo-[3H]Inositol was purchased from Amersham Japan, 
Tokyo. Fura2-(acetoxymethyl)ester was obtained from Dojin, 
Kumamoto, Japan. 
Rabbit platelet-rich plasma was prepared from freshly drawn 
blood and mixed with PGEi (0.5 pg/ml). Platelets were 
sedimented by centrifugation at 1200 x g for 15 min and 
resuspended at 2 x lo9 cells/ml in a resuspension buffer 
(137 mM NaCI, 2.7 mM KCI, 1.0 mM MgClz, 3.8 mM 
NaHzPOd, 3.8 mM Hepes, 5.6 mM glucose and 0.035% bovine 
serum albumin, pH 7.35). If necessary, platelets were incubated 
with 1 ,uM fura2-AM or 50pCi/ml myo-[sH]inositol for 1 or 
2 h at room temperature in the presence of 0.5 /g/ml PGEi. 
Platelets were sedimented onto 40% bovine serum albumin, 
isolated with a column of Sepharose 2B, and resuspended in the 
resuspension buffer at 5 x 10s cells/ml. CaClz (1 mM) or 
EGTA (2.5 mM) was added to the platelets 2 min before 
stimulation. Secretion of ATP was monitored by a PICA ag- 
gregometer (Chrono-log) using a luciferase-luciferin reagent, 
Chronolume (Chrono-log). The fluorescence signal of fura 
was monitored while stirring at 37°C with a CAF-100 Ca*+ 
analyzer (Japan Spectroscopic Co., Ltd, Tokyo). The Ca’+ 
concentration was calculated as described elsewhere [8]. To the 
[‘Hlinositol-labeled platelets, 15 mM LiCl was added 30 min 
before stimulation. [3H]Inositol phosphates were extracted and 
separated as described by Berridge et al. [9]. 
3. RESULTS AND DISCUSSION 
As shown in fig. 1, U46619 dose-dependently in- 
duced shape change, aggregation and secretion of 
ATP. However, S-145 induced only shape change 
even at the highest concentration (1 PM). This dif- 
ference in response should not have been caused by 
the difference between binding affinities of the 
compounds to TXAJPGHz receptor, since a 
binding study with radiolabeled U46619 has re- 
vealed that the affinity of S-145 to the receptor of 
rabbit platelet is higher than that of U46619 [6]. 
Fig.2 shows intracellular Ca2+ mobilization dur- 
ing stimulation with U46619 and S-145. Both 
U46619 and S-145 rapidly elevated cytoplasmic 
Ca2+ concentration, Which reached a maximum 
within 10 s. S-145-induced Ca2+ elevation was 
rapidly decreased to the resting level while Ca2+ 
concentration maintained a somewhat higher value 
than the resting level when platelets were stimu- 
lated with U46619. In order to determine whether 
Ca2+ elevation is essential for inducing shape 
change, the response of platelets to S-145 was 
examined in the absence of extracellular Ca2+. As 
shown in table 1, depletion of Ca2+ did not affect 
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Fig.1. Shape change, aggregation and secretion of ATP. 
U46619 (A) or S-145 (B) was added at the arrow. Increase and 
decrease of light transmission represent shape change and 
aggregation, respectively. ATP release was monitored with 
PICA aggregometer (Chrono-log). 
S-145-induced shape change. However, in the 
absence of external Ca2+, S-145 induced only a 
slight increase of cytoplasmic Ca2+ which seemed 
to be too small to induce Ca2+-dependent 
responses. This result suggests that a rise in Ca2+ 
is not necessary for shape change. 
As phospholipase C is thought to have a central 
role in platelet activation, we studied the 
phospholipase C action during stimulation with 
U46619 and S-145 by measuring the increase of 
[3H]inositol phosphates in [3H]inositol-labeled 
platelets. Fig.3 shows inositol phosphate forma- 
tion during stimulation with 1 PM U46619 and 
1 PM S-145. A significant increase of inositol 
phosphates was observed when platelets were 
stimulated with U46619. However, S-145 did not 
change the level of inositol phosphates. This 
finding indicates that phospholipase C acted 
during stimulation with U46619 but not during 
stimulation with S-145. 
Platelet shape change is associated with many 
cellular processes including repositioning of the 
equatorial band of microtubules, polymerization 
of actin, phosphorylation of myosin light chains, 
formation of actomyosin, centralization of 
secretory granules, and formation of filopodia and 
pseudopodia [lo-131. Movement of the cyto- 
skeleton is considered to be involved in these 
responses. However, the factor triggering the 
response of the cytoskeleton has not been as- 
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Fig.2. Change in cytosolic Ca*’ concentration. FuraZ-loaded 
platelets were stimulated with U46619 (A) or S-145 (B). The 
fluorescence ratio, obtained by dividing the fluorescence at 
340 nm by that at 380 nm, was determined with CAF-100 Ca*+ 
analyzer. The emission wavelength was 500 nm. 
certained. Ca2+ is one of the candidates for the 
trigger. However, our results indicate that shape 
change can be induced without Ca2+ elevation. 
Simpson et al. [ 141 also reported that a low dose of 
U44069 induces shape change of human platelets 
without Ca2+ elevation. It has been suggested that 
either diacylglycerol or phosphatidylinositol 
4,5bisphosphate may play a part in forming a 
nucleation site for the polymerization of actin 
[ 15,161. However, stimulation of inositol lipid 
turnover is not induced by S-145. Although the 
putative alternative signal transduction mechanism 
remains unclear, the interaction between the recep- 
Table 1 
Effect of extracellular Ca*+ on S-145induced Ca’+ 
mobilization and shape change 
A [Ca*+]i 
(nM) 
Shape change 
I%) 
A. 1 mM Ca*+ 227 + 33 100+ 9 
B. No Ca*+ 17* 3 99 f 10 
Platelets .were stimulated with 1 PM S-145 in the presence of 
1 mM Ca*+ (A) or in the presence of 2.5 mM EGTA with no 
added Ca*+ (B). A[Ca*+]i is the measured increment over the 
resting level. Shape change is measured as the Vo of the maximal 
increment in transmission. The data are mean f SD for five 
experiments 
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Fig.3. Formation of inositol phosphates. [3H]1nositol-labeled 
platelets were stimulated with 1 pM U46619 (A) or 1 pM S-145 
(B). Radioactivity of inositol I-monophosphate (IPi, 0), 
inositol 1,4-bisphosphate (IPz, A) and inositol 1,4,5tris- 
phosphate (IPs, l ) is represented. 
tor and the cytoskeleton would be a very in- 
teresting subject for further study. 
IP3 is thought to release Ca2+ from the in- 
tracellular Ca2+ store [3]. In this study, however, 
S-145 induced Ca2+ mobilization without increase 
of IP3. This finding suggests the presence of some 
factor other than IP3 which induces Ca2+ mobiliza- 
tion. The result that depletion of external Ca2+ 
severely reduced Ca2+ mobilization suggests that 
influx of external Ca2+ may be involved in 
S-145-induced Ca2+ mobilization. However, the 
release of Ca2+ from the intracellular store must 
occur since S-145 causes a slight increase in Ca2+ 
in the absence of external Ca2+. It has been 
reported that stimulation of rat platelets with 
U46619 and stimulation of human platelets with 
ADP also raises Ca2+ without IP3 formation 
[ 17,181, but no precise mechanism has been 
offered. 
We have reported earlier that only shape change 
is induced when rat platelets are stimulated with 
U46619 while aggregation and secretion are in- 
duced by the synergistic action of U46619 and col- 
lagen, and that induction of aggregation and 
secretion is accompanied by activation of 
phospholipase C [17,19,20]. The results of the pre- 
sent study also suggest an important role of 
phospholipase C in the induction of aggregation 
and secretion. Clearly, Ca2+ mobilization is not ‘a 
sufficient signal for aggregation and secretion. 
During stimulation with U46619, IP3 formed by 
the action of phospholipase C may reinforce Ca2+ 
311 
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movement. U46619 induced a higher maximum 
Ca2+ and a more sustained level of Ca2+ than 
S-145, which may have led to aggregation and 
secretion. However, the maximum Ca2+ concen- 
tration is unlikely to be related to the occurrence of 
aggregation and secretion, since 1 ,LLM S-145, 
which induced nearly the same level of peak Ca2+ 
as 100 nM U46619, induced only shape change, 
whereas 100 nM U46619 also induced aggregation 
and secretion. In U46619 stimulation of platelets, 
diacylglycerol, an activator of protein kinase C, 
must be generated via phospholipase C. Some 
reports have indicated that protein kinase C sup- 
presses platelet function [21-231. However, pro- 
tein kinase C probably also has a role in platelet 
activation [2]. Therefore, in addition to the rein- 
forced Ca2+ mobilization, activation of protein 
kinase C may be essential to U46619-induced ag- 
gregation and secretion. 
Why the response induced by S-145 differs from 
that induced by U46619 is not yet clear. S-145 in- 
duces Ca2+ mobilization, and U46619 induces the 
phospholipase C response in addition to Ca2+ 
mobilization. More precise analyses of the interac- 
tion between the receptor and these compounds 
may provide the answers. 
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